 | • レポートコード：MRC23Q36307 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、86ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のプリン作動性受容体拮抗薬市場について調査・分析し、世界のプリン作動性受容体拮抗薬市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（P2Y、P2X）、用途別セグメント分析（心臓病、脳卒中、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Sanofi、Bristol Myers Squibb、Apotex、Mylan、AstraZeneca、Chiesi Farmaceutici、Bayer、Zydus Cadila Healthcare、Sun Pharmaceutical、Huahai Pharmaceuticalなどが含まれています。世界のプリン作動性受容体拮抗薬市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、プリン作動性受容体拮抗薬市場規模を推定する際に考慮しました。本レポートは、プリン作動性受容体拮抗薬の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、プリン作動性受容体拮抗薬に関するビジネス上の意思決定に役立てることを目的としています。 ・プリン作動性受容体拮抗薬市場の概要 - プリン作動性受容体拮抗薬のタイプ別セグメント - 世界のプリン作動性受容体拮抗薬市場規模：タイプ別分析（P2Y、P2X） - プリン作動性受容体拮抗薬の用途別セグメント - 世界のプリン作動性受容体拮抗薬市場規模：用途別分析（心臓病、脳卒中、その他） - 世界のプリン作動性受容体拮抗薬市場規模予測（2018年-2029年） ・プリン作動性受容体拮抗薬市場の成長トレンド - プリン作動性受容体拮抗薬の地域別市場規模（2018年-2029年） - プリン作動性受容体拮抗薬市場ダイナミクス - プリン作動性受容体拮抗薬の業界動向 - プリン作動性受容体拮抗薬市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：P2Y、P2X - 世界のプリン作動性受容体拮抗薬のタイプ別市場規模（2018年-2023年） - 世界のプリン作動性受容体拮抗薬のタイプ別市場規模（2024年-2029年） ・用途別セグメント：心臓病、脳卒中、その他 - 世界のプリン作動性受容体拮抗薬の用途別市場規模（2018年-2023年） - 世界のプリン作動性受容体拮抗薬の用途別市場規模（2024年-2029年） ・プリン作動性受容体拮抗薬の地域別市場規模 - 北米のプリン作動性受容体拮抗薬市場規模（2018年-2029年） - アメリカのプリン作動性受容体拮抗薬市場規模（2018年-2029年） - ヨーロッパのプリン作動性受容体拮抗薬市場規模（2018年-2029年） - アジア太平洋のプリン作動性受容体拮抗薬市場規模（2018年-2029年） - 中国のプリン作動性受容体拮抗薬市場規模（2018年-2029年） - 日本のプリン作動性受容体拮抗薬市場規模（2018年-2029年） - 韓国のプリン作動性受容体拮抗薬市場規模（2018年-2029年） - インドのプリン作動性受容体拮抗薬市場規模（2018年-2029年） - オーストラリアのプリン作動性受容体拮抗薬市場規模（2018年-2029年） - 中南米のプリン作動性受容体拮抗薬市場規模（2018年-2029年） - 中東・アフリカのプリン作動性受容体拮抗薬市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Sanofi、Bristol Myers Squibb、Apotex、Mylan、AstraZeneca、Chiesi Farmaceutici、Bayer、Zydus Cadila Healthcare、Sun Pharmaceutical、Huahai Pharmaceutical ・アナリストの観点/結論 ・調査方法とデータソース |
Drugs That Bind to Purine Receptors and Block Their Activation, Thereby Inhibiting Platelets, Are Mostly Used to Reduce the Risk of Heart Disease and Stroke in High-risk Groups.
Highlights
The global Purinergic Receptor Antagonists market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Purinergic Receptor Antagonists is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Purinergic Receptor Antagonists is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Purinergic Receptor Antagonists in Heart Disease is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Purinergic Receptor Antagonists include Sanofi, Bristol Myers Squibb, Apotex, Mylan, AstraZeneca, Chiesi Farmaceutici, Bayer, Zydus Cadila Healthcare and Sun Pharmaceutical, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Purinergic Receptor Antagonists, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Purinergic Receptor Antagonists.
The Purinergic Receptor Antagonists market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Purinergic Receptor Antagonists market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Purinergic Receptor Antagonists companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Sanofi
Bristol Myers Squibb
Apotex
Mylan
AstraZeneca
Chiesi Farmaceutici
Bayer
Zydus Cadila Healthcare
Sun Pharmaceutical
Huahai Pharmaceutical
Segment by Type
P2Y
P2X
Segment by Application
Heart Disease
Stroke
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Purinergic Receptor Antagonists companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Purinergic Receptor Antagonists Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 P2Y
1.2.3 P2X
1.3 Market by Application
1.3.1 Global Purinergic Receptor Antagonists Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Heart Disease
1.3.3 Stroke
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Purinergic Receptor Antagonists Market Perspective (2018-2029)
2.2 Purinergic Receptor Antagonists Growth Trends by Region
2.2.1 Global Purinergic Receptor Antagonists Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Purinergic Receptor Antagonists Historic Market Size by Region (2018-2023)
2.2.3 Purinergic Receptor Antagonists Forecasted Market Size by Region (2024-2029)
2.3 Purinergic Receptor Antagonists Market Dynamics
2.3.1 Purinergic Receptor Antagonists Industry Trends
2.3.2 Purinergic Receptor Antagonists Market Drivers
2.3.3 Purinergic Receptor Antagonists Market Challenges
2.3.4 Purinergic Receptor Antagonists Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Purinergic Receptor Antagonists Players by Revenue
3.1.1 Global Top Purinergic Receptor Antagonists Players by Revenue (2018-2023)
3.1.2 Global Purinergic Receptor Antagonists Revenue Market Share by Players (2018-2023)
3.2 Global Purinergic Receptor Antagonists Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Purinergic Receptor Antagonists Revenue
3.4 Global Purinergic Receptor Antagonists Market Concentration Ratio
3.4.1 Global Purinergic Receptor Antagonists Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Purinergic Receptor Antagonists Revenue in 2022
3.5 Purinergic Receptor Antagonists Key Players Head office and Area Served
3.6 Key Players Purinergic Receptor Antagonists Product Solution and Service
3.7 Date of Enter into Purinergic Receptor Antagonists Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Purinergic Receptor Antagonists Breakdown Data by Type
4.1 Global Purinergic Receptor Antagonists Historic Market Size by Type (2018-2023)
4.2 Global Purinergic Receptor Antagonists Forecasted Market Size by Type (2024-2029)
5 Purinergic Receptor Antagonists Breakdown Data by Application
5.1 Global Purinergic Receptor Antagonists Historic Market Size by Application (2018-2023)
5.2 Global Purinergic Receptor Antagonists Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Purinergic Receptor Antagonists Market Size (2018-2029)
6.2 North America Purinergic Receptor Antagonists Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Purinergic Receptor Antagonists Market Size by Country (2018-2023)
6.4 North America Purinergic Receptor Antagonists Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Purinergic Receptor Antagonists Market Size (2018-2029)
7.2 Europe Purinergic Receptor Antagonists Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Purinergic Receptor Antagonists Market Size by Country (2018-2023)
7.4 Europe Purinergic Receptor Antagonists Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Purinergic Receptor Antagonists Market Size (2018-2029)
8.2 Asia-Pacific Purinergic Receptor Antagonists Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Purinergic Receptor Antagonists Market Size by Region (2018-2023)
8.4 Asia-Pacific Purinergic Receptor Antagonists Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Purinergic Receptor Antagonists Market Size (2018-2029)
9.2 Latin America Purinergic Receptor Antagonists Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Purinergic Receptor Antagonists Market Size by Country (2018-2023)
9.4 Latin America Purinergic Receptor Antagonists Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Purinergic Receptor Antagonists Market Size (2018-2029)
10.2 Middle East & Africa Purinergic Receptor Antagonists Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Purinergic Receptor Antagonists Market Size by Country (2018-2023)
10.4 Middle East & Africa Purinergic Receptor Antagonists Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Detail
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Purinergic Receptor Antagonists Introduction
11.1.4 Sanofi Revenue in Purinergic Receptor Antagonists Business (2018-2023)
11.1.5 Sanofi Recent Development
11.2 Bristol Myers Squibb
11.2.1 Bristol Myers Squibb Company Detail
11.2.2 Bristol Myers Squibb Business Overview
11.2.3 Bristol Myers Squibb Purinergic Receptor Antagonists Introduction
11.2.4 Bristol Myers Squibb Revenue in Purinergic Receptor Antagonists Business (2018-2023)
11.2.5 Bristol Myers Squibb Recent Development
11.3 Apotex
11.3.1 Apotex Company Detail
11.3.2 Apotex Business Overview
11.3.3 Apotex Purinergic Receptor Antagonists Introduction
11.3.4 Apotex Revenue in Purinergic Receptor Antagonists Business (2018-2023)
11.3.5 Apotex Recent Development
11.4 Mylan
11.4.1 Mylan Company Detail
11.4.2 Mylan Business Overview
11.4.3 Mylan Purinergic Receptor Antagonists Introduction
11.4.4 Mylan Revenue in Purinergic Receptor Antagonists Business (2018-2023)
11.4.5 Mylan Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Detail
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Purinergic Receptor Antagonists Introduction
11.5.4 AstraZeneca Revenue in Purinergic Receptor Antagonists Business (2018-2023)
11.5.5 AstraZeneca Recent Development
11.6 Chiesi Farmaceutici
11.6.1 Chiesi Farmaceutici Company Detail
11.6.2 Chiesi Farmaceutici Business Overview
11.6.3 Chiesi Farmaceutici Purinergic Receptor Antagonists Introduction
11.6.4 Chiesi Farmaceutici Revenue in Purinergic Receptor Antagonists Business (2018-2023)
11.6.5 Chiesi Farmaceutici Recent Development
11.7 Bayer
11.7.1 Bayer Company Detail
11.7.2 Bayer Business Overview
11.7.3 Bayer Purinergic Receptor Antagonists Introduction
11.7.4 Bayer Revenue in Purinergic Receptor Antagonists Business (2018-2023)
11.7.5 Bayer Recent Development
11.8 Zydus Cadila Healthcare
11.8.1 Zydus Cadila Healthcare Company Detail
11.8.2 Zydus Cadila Healthcare Business Overview
11.8.3 Zydus Cadila Healthcare Purinergic Receptor Antagonists Introduction
11.8.4 Zydus Cadila Healthcare Revenue in Purinergic Receptor Antagonists Business (2018-2023)
11.8.5 Zydus Cadila Healthcare Recent Development
11.9 Sun Pharmaceutical
11.9.1 Sun Pharmaceutical Company Detail
11.9.2 Sun Pharmaceutical Business Overview
11.9.3 Sun Pharmaceutical Purinergic Receptor Antagonists Introduction
11.9.4 Sun Pharmaceutical Revenue in Purinergic Receptor Antagonists Business (2018-2023)
11.9.5 Sun Pharmaceutical Recent Development
11.10 Huahai Pharmaceutical
11.10.1 Huahai Pharmaceutical Company Detail
11.10.2 Huahai Pharmaceutical Business Overview
11.10.3 Huahai Pharmaceutical Purinergic Receptor Antagonists Introduction
11.10.4 Huahai Pharmaceutical Revenue in Purinergic Receptor Antagonists Business (2018-2023)
11.10.5 Huahai Pharmaceutical Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details